These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39196505)

  • 21. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
    Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD
    Hepatology; 2024 May; ():. PubMed ID: 38739848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From NAFLD to MASLD: When metabolic comorbidity matters.
    Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H
    Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions.
    Beygi M; Ahi S; Zolghadri S; Stanek A
    Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.
    Kang MK; Song JE; Loomba R; Park SY; Tak WY; Kweon YO; Lee YR; Park JG
    Sci Rep; 2024 Oct; 14(1):22917. PubMed ID: 39358447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality.
    Oh R; Kim S; Cho SH; Kim J; Lee YB; Jin SM; Hur KY; Kim G; Kim JH
    Diabetes Metab J; 2024 Aug; ():. PubMed ID: 39197834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Why MASLD Lags Behind MAFLD: A Critical Analysis of Diagnostic Criteria Evolution in Metabolic Dysfunction-Associated Liver Diseases.
    Alboraie M; Butt AS; Piscoya A; Dao Viet H; Hotayt B; Al Awadhi S; Bahcecioglu IH; Alkhalidi N; Al Mahtab M; Méndez-Sánchez N
    Med Sci Monit; 2024 Jul; 30():e945198. PubMed ID: 39075772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population.
    Männistö V; Salomaa V; Jula A; Lundqvist A; Männistö S; Perola M; Åberg F
    JHEP Rep; 2024 Oct; 6(10):101172. PubMed ID: 39430577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus.
    Chen L
    World J Hepatol; 2023 Dec; 15(12):1253-1257. PubMed ID: 38223415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function.
    Medina-Julio D; Ramírez-Mejía MM; Cordova-Gallardo J; Peniche-Luna E; Cantú-Brito C; Mendez-Sanchez N
    Med Sci Monit; 2024 Jan; 30():e943417. PubMed ID: 38282346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
    Han E; Lee BW; Kang ES; Cha BS; Ahn SH; Lee YH; Kim SU
    Metabolism; 2024 Mar; 152():155789. PubMed ID: 38224909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease.
    Li Y; Guo Y; Tan S
    Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102320. PubMed ID: 38484840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
    Younossi ZM; Paik JM; Al Shabeeb R; Golabi P; Younossi I; Henry L
    Hepatology; 2022 Nov; 76(5):1423-1437. PubMed ID: 35363908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between antibiotic use and cardiovascular diseases in metabolic dysfunction-associated steatotic liver disease: A nationally representative retrospective cohort study.
    Kang JH; Park SJ; Jeong S; Park YJ; Kim HJ; Song J; Choi J; Park S; Kim J; Lee H; Chang J; Son JS; Park SM
    Hepatol Res; 2024 Sep; ():. PubMed ID: 39345177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.